Satellos Bioscience Inc. (NASDAQ:MSLE) Receives $19.75 Average Price Target from Analysts

Satellos Bioscience Inc. (NASDAQ:MSLE) has earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $19.75.

MSLE has been the subject of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Monday, May 11th. Wells Fargo & Company set a $18.00 price target on Satellos Bioscience in a report on Thursday, July 9th. Leerink Partners began coverage on Satellos Bioscience in a report on Monday, April 6th. They set an “outperform” rating and a $20.00 price target for the company. Guggenheim began coverage on Satellos Bioscience in a research report on Tuesday, April 28th. They set a “buy” rating and a $23.00 price objective for the company. Finally, HC Wainwright boosted their price objective on shares of Satellos Bioscience from $11.00 to $18.00 and gave the company a “buy” rating in a report on Thursday, July 9th.

Satellos Bioscience Stock Performance

Satellos Bioscience stock opened at $8.95 on Wednesday. The company has a 50 day moving average price of $7.11. The stock has a market cap of $186.52 million, a PE ratio of -5.59 and a beta of 1.53. Satellos Bioscience has a 1-year low of $4.64 and a 1-year high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.02). On average, research analysts forecast that Satellos Bioscience will post -1.69 earnings per share for the current year.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.